US Stock MarketDetailed Quotes
CGTX Cognition Therapeutics
- 0.407
- -0.021-4.84%
Close Nov 25 16:00 ET
- 0.410
- +0.003+0.76%
Post 20:01 ET
16.91MMarket Cap-423P/E (TTM)
0.479High0.377Low47.27MVolume0.479Open0.428Pre Close25.50MTurnover133.72%Turnover RatioLossP/E (Static)41.55MShares2.95052wk High1.17P/B14.39MFloat Cap0.34052wk Low--Dividend TTM35.35MShs Float13.800Historical High--Div YieldTTM23.92%Amplitude0.340Historical Low0.539Avg Price1Lot Size
About Cognition Therapeutics Company
Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Company Profile
SymbolCGTX
Company NameCognition Therapeutics
Listing DateOct 8, 2021
Issue Price12.00
Founded2007
CEOMs. Lisa Ricciardi
MarketNASDAQ
Employees28
Fiscal Year Ends12-31
Address2500 Westchester Avenue
CityPurchase
ProvinceNew York
CountryUnited States of America
Zip Code10577
Phone1-412-481-2210
Websitehttp://www.cogrx.com
Company Executives
- Name
- Position
- Salary
- Lisa Ricciardi
- Director, Chief Executive Officer and President
- 1.66M
- Dr. Anthony Caggiano, M.D.,PhD
- Chief Medical Officer and Head of R&D
- 972.12K
- John Doyle
- Chief Financial Officer and Principal Accounting Officer
- 737.26K
- Jack A. Khattar
- Chairman of the Board
- 145.11K
- Ellen B. Richstone
- Independent Director
- 83.61K
- Dr. Aaron G.L. Fletcher, PhD
- Independent Director
- 74.61K
- Dr. Brett P. Monia, PhD
- Independent Director
- 79.61K
- Peggy Wallace
- Independent Director
- 76.11K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data